Here are the 424B prospectus supplements from Reviva Pharma Holdings Inc (RVPH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.
Reviva Pharmaceuticals Holdings is conducting a primary offering of 27,000,000 shares of common stock, together with Series E warrants for up to 27,000,000 shares and Series F warrants for up to 27,000,000 shares, at a combined public offering price of $0.335 per share and accompanying warrants, for maximum gross proceeds of $9,045,000. After placement fees and expenses, net proceeds are estimated at about $8.1 million, with the company planning to use the cash for research and development of its lead drug brilaroxazine and for working capital.
The offering is a best-efforts, no-minimum deal led by A.G.P., so Reviva may raise substantially less than the maximum and investor funds will not be placed in escrow. Common shares outstanding would be 96,337,119 after the transaction, before any warrant exercises, resulting in dilution for new and existing holders. The Series E warrants are exercisable immediately at $0.335 for five years, while the Series F warrants share the same exercise price with a 12‑month term.
Reviva highlights positive Phase 3 RECOVER-1 data and one‑year open‑label extension results in schizophrenia and plans to seek an FDA meeting in Q4‑2025 to discuss a potential NDA based on existing trials, with a possible NDA filing targeted for Q2‑2026 if the agency response is favorable and additional financing is secured.
Reviva Pharmaceuticals plans a primary offering of common stock, together with Series E and Series F common warrants, and pre-funded warrants sold in lieu of common stock for certain large investors. Each share or pre-funded warrant will be sold with one Series E warrant and one Series F warrant, both exercisable immediately, with the Series E warrant having a five-year term and the Series F warrant a 12‑month term. The transaction is a best‑efforts, no‑minimum offering led by A.G.P./Alliance Global Partners, so proceeds to Reviva will depend on actual investor demand.
Reviva expects to use net proceeds mainly to fund research and development for its lead drug brilaroxazine and for working capital and general corporate purposes. The prospectus highlights positive Phase 3 RECOVER-1 and one‑year open‑label extension results in schizophrenia and outlines a potential path to an NDA submission based on existing Phase 2 and Phase 3 data. The company cautions that investors may face dilution, that the warrants will not be listed, and that limited proceeds could constrain its ability to execute its business plan.
Reviva Pharmaceuticals has announced a public offering of 20,000,000 shares of common stock at $0.50 per share, along with Series C and Series D Common Warrants. The total offering value is $10 million, with expected net proceeds of $9.3 million before expenses.
Key offering details:
- Each share comes with two warrants: one Series C warrant (5-year term) and one Series D warrant (12-month term)
- Both warrant series have an exercise price of $0.50 per share
- A.G.P./Alliance Global Partners serving as sole Placement Agent, receiving 7% fee (3.5% for certain investors)
- No minimum offering requirement or escrow arrangement
- Expected closing date: June 27, 2025
The offering represents a significant discount to the last reported share price of $0.8049 on Nasdaq (RVPH). The company notes it is a "smaller reporting company" and warns investors of potential risks, including limited warrant liquidity as no trading market exists or is planned for the warrants.
Reviva Pharmaceuticals Holdings has announced a new securities offering including shares of common stock, Series C and D Common Warrants, and Pre-Funded Warrants. The offering includes:
- Common stock (at $0.8049 per share last trading price) with accompanying warrants
- Series C Common Warrants with 5-year expiration and immediate exercisability
- Series D Common Warrants with 12-month expiration and immediate exercisability
- Pre-Funded Warrants for investors who would exceed 4.99% (or 9.99%) ownership
Key Details: A.G.P./Alliance Global Partners is serving as sole Placement Agent, receiving a 7% fee (3.5% for certain investors). The offering has no minimum requirement and will terminate by June 2025 unless completed sooner. Trading under symbol RVPH on Nasdaq Capital Market, the company qualifies as a "smaller reporting company." Proceeds will be immediately available for company use, though total offering amount remains undetermined.